G2083 Insurance Policy Changes

HCPCS G2083 is officially defined as "Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation." HCPCS G2083 is referenced in 11 tracked payer policy changes from Anthem BCBS, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G2083 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.